Teclison Ltd.
Clinical trials sponsored by Teclison Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy targets Hard-to-Treat liver and stomach cancers Results expected Dec 2026 (estimated)
- New combo therapy targets liver metastases in hard-to-treat cancers Results expected Mar 2027 (estimated)
-
New combo attack on liver cancer: drug activated by Tumor's own hypoxia
Disease control Recruiting nowThis early-phase trial tests a drug called tirapazamine, which becomes active only in low-oxygen (hypoxic) areas of tumors, combined with a standard procedure that blocks blood flow to the tumor (transarterial embolization). The goal is to find the best dose and see if the combin…
Phase 1/2 • Sponsor: Teclison Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New combo therapy targets Hard-to-Treat liver and stomach cancers
Disease control Recruiting nowThis study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure c…
Phase 2 • Sponsor: Teclison Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy targets liver metastases in hard-to-treat cancers
Disease control Recruiting nowThis study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a liver-directed procedure (TATE) that delivers a chemotherapy-like drug directly to the …
Phase 2 • Sponsor: Teclison Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC